11:40 AM EDT, 07/15/2025 (MT Newswires) -- Jazz Pharmaceuticals' ( JAZZ ) stock offers "an attractive entry point" for investors following its recent decline with the outlook bolstered by expansion in the oncology business and "resilience" in neuroscience, Deutsche Bank said Tuesday in a note.

The company will "enter a period of value creation" from H2 through 2027, driven by growth in revenue, earnings and free cash flow, the report said.

"The company's focus is on developing and commercializing more innovative biopharma assets, though the stock continues to trade at depressed multiples relative to commercial-stage peers,"

Deutsche Bank said.

Free cash flow may increase to $1.7 billion by 2032 from $1 billion, partly supported by high single-digit sales growth underpinned by rising oncology revenue, the report said.

Deutsche Bank initiated coverage of Jazz Pharmaceuticals ( JAZZ ) with a buy rating and $152 price target.

Price: 111.66, Change: +0.22, Percent Change: +0.20